Insights into Biotech Ownership and CRISPR Therapeutics Challenges

Genetically edited humans are already here. Gene editing has massive implications for treating chronic illnesses and even the food we eat. So what does this mean for your investments and, y'know, possibly humanity? Ricky Mulvey talks with Motley Fool Advisor Karl Thiel about: - How CRISPR works - Some of the possibilities for CRISPR, from sickle cell cures to drought-resistant crops - How investors can approach investing in gene therapies - Biotech metrics to watch.

Companies mentioned: BLUE, CRSP, GILD, EDIT, VRTX, NTLA

Host: Ricky Mulvey Guest: Karl Theil Engineers: Tim Sparks, Dan Boyd

Learn more about your ad choices. Visit megaphone.fm/adchoices